

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB2005/001089

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K45/06 A61K31/337 A61K31/517 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/47212 A (ASTRAZENECA UK LIMITED; ZENECA-PHARMA S.A) 17 August 2000 (2000-08-17) cited in the application page 84, line 30 - page 86, line 23; example 240	1-16
A	MALIK A K HANS-PETER GERBER: "Targeting VEGF ligands and receptors in cancer" TARGETS, ELSEVIER, vol. 2, no. 2, 1 April 2003 (2003-04-01), pages 48-57, XP004886645 ISSN: 1477-3627 page 51, left-hand column, paragraph 3 page 50, right-hand column, paragraph 2 page 55; table 3 page 49, right-hand column, paragraph 5 ----- -/--	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

31 August 2006

Date of mailing of the international search report

07/09/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB2005/001089

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARME D: "THE IMPACT OF ANTI-ANGIOGENIC AGENTS ON CANCER THERAPY" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 129, no. 11, 2003, pages 607-620, XP001182072 ISSN: 0171-5216 page 616, left-hand column, paragraph 2 page 617, left-hand column page 614, left-hand column, paragraph 2; table 3	1-3, 7-12, 14-16
P,X	----- WO 2005/004871 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED) 20 January 2005 (2005-01-20) page 15	11
P,X	----- WO 2004/096224 A (BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOEHRINGER INGELHEIM PHARMA G) 11 November 2004 (2004-11-11), pages 70-71	1-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/001089

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB2005/001089

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0047212	A	17-08-2000	AT 298237 T	15-07-2005
			AU 763618 B2	31-07-2003
			AU 2447500 A	29-08-2000
			BR 0008128 A	13-02-2002
			CA 2362715 A1	17-08-2000
			CN 1346271 A	24-04-2002
			CN 1597667 A	23-03-2005
			CZ 20012889 A3	14-11-2001
			DE 60020941 D1	28-07-2005
			DE 60020941 T2	11-05-2006
			EE 200100409 A	16-12-2002
			ES 2242596 T3	16-11-2005
			HK 1041212 A1	02-12-2005
			HU 0104964 A2	29-04-2002
			ID 30552 A	20-12-2001
			IS 6022 A	24-07-2001
			JP 2002536414 T	29-10-2002
			MX PA01008182 A	20-08-2003
			NO 20013882 A	09-10-2001
			NZ 513204 A	30-04-2004
			NZ 530832 A	27-05-2005
			PL 350565 A1	16-12-2002
			PT 1154774 T	31-10-2005
			SK 11402001 A3	07-01-2002
			TR 200102314 T2	21-01-2002
			TR 200500745 T2	23-05-2005
			UA 73932 C2	15-01-2002
			US 2006004017 A1	05-01-2006
			US 7074800 B1	11-07-2006
			ZA 200106340 A	01-11-2002
WO 2005004871	A	20-01-2005	AU 2004255023 A1	20-01-2005
			CA 2531643 A1	20-01-2005
			EP 1651227 A1	03-05-2006
			MX PA06000413 A	17-03-2006
			US 2006160775 A1	20-07-2006
WO 2004096224	A	11-11-2004	AU 2004233576 A1	11-11-2004
			BR PI0409919 A	25-04-2006
			CA 2523868 A1	11-11-2004
			MX PA05011656 A	15-12-2005